SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Investors are actively debating the long-term potential of the 4CHAN token, positioning it as a foundational "index fund" of meme culture with significant upside should it capture broader adoption. While some community members remain skeptical of volatility and price action, proponents emphasize the token's cultural roots, low market capitalization, and historical significance as catalysts for a potential major rally.

Asana, Inc. engages in the business of developing a work management platform that helps organizations orchestrate work from daily tasks to cross-functional strategic initiatives. The company was founded by Dustin Moskovitz and Justin Michael Rosenstein on December 16, 2008 and is headquartered in San Francisco, CA.

Asana Inc - Ordinary Shares - Class A

Asana Inc

Asana is seeing significant market activity driven by aggressive insider accumulation, specifically from CEO Dustin Moskovitz, who has been consistently purchasing large volumes of shares. While the stock faces ongoing pressure from high operating losses and intense competition, the community is closely monitoring these insider buys as a potential signal for a turnaround or a strategic shift, leading to speculation about a possible future acquisition or long-term value play.

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic Plc

Medtronic is capturing market attention following a fiscal third-quarter earnings report that surpassed analyst expectations on both earnings and revenue, despite initial share price volatility tied to cautious full-year guidance and tariff-related impacts. The community is actively debating the company's long-term value, with active discussions focusing on its dividend reliability, potential for M&A-driven growth in cardiovascular and diabetes segments, and the impact of the upcoming MiniMed spinoff.

iShares Trust - iShares 1-3 Year Treasury Bond ETF

iShares 1-3 Year Treasury Bond ETF

SHY is trending as investors navigate a complex macro environment defined by persistent inflation, evolving Fed rate cut expectations, and shifting fiscal policy, including ongoing debates over tariffs and government spending. Market participants are closely monitoring short-term Treasury yields and liquidity signals as they weigh the potential for a 'higher-for-longer' rate environment against incoming economic data.

Shido

Shido is gaining significant community attention as the project continues to expand its L1 ecosystem, fueled by the recent launch of BubbleStaking and progress toward the Nova EVM architecture. Investors are actively discussing the platform's focus on high-performance infrastructure, including instant finality and the upcoming transition to an agentic economy, as they watch for further milestones on the network roadmap.

Pippin is an SVG unicorn drawn using the latest LLM benchmarks on ChatGPT 4o. It is an autonomous AI agent on X. Pippin was created by Yohei Nakajima, a recognised innovator and thought leader in the Al VC space (followed by Jeff Bezos and Marc Andreessen). He is known for his build-in-public approach and has been at the forefront of the ‘AI for VC’ movement, launching over 100+ AI-driven prototypes, automation agents &amp; open-source projects.  His most notable build is BabyAGI (March 2023), the first popular open-source autonomous agent with task-planning capability. The project went viral on Twitter amassing millions of impressions and resulting in tens of thousands of GitHub stars, dozens of Arxiv citations, coverage across major online media publications globally, and many speaker engagements including the inaugural TED AI in San Francisco.

pippin

PIPPIN is currently a focal point for intense debate, as traders weigh its significant volatility and historical price swings against accusations of market manipulation and centralized control by developers. While some in the community see it as a high-potential AI-driven meme play primed for short squeezes, many others warn of scam risks due to high holder concentration and suspicious volume patterns.

Tower Semiconductor Ltd. engages in providing semiconductor solutions. It also offers technology and manufacturing platforms for integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical, and aerospace and defense. It focuses on creating positive and sustainable impact on the world through long term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, integrated power management (BCD and 700V), and MEMS. Its designs enable a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. The company was founded in 1993 and is headquartered in Migdal Haemek, Israel.

Tower Semiconductor Ltd.

Tower Semiconductor is currently in the spotlight as investors speculate on the final regulatory outcome of its high-profile acquisition deal with Intel. The community is actively debating the stock's valuation and the potential for a reversal or significant move, with many traders closely monitoring the deadline for the merger's approval versus the prospects of the company as a standalone entity.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is seeing heightened community engagement as investors speculate on upcoming network upgrades, specifically the launch of smart contracts and potential tier-one exchange listings. While some participants are wary of volatility and the lack of major exchange support, others remain focused on long-term scaling benefits and the potential for a broader institutional adoption of its blockDAG architecture.

Shutterstock, Inc. engages in the provision of a global creative platform. The company offers data, distribution, and services. Its contents include images, footage, music, three dimensional (3D) models, and generative artificial intelligence. The company was founded by Jonathan Evan Oringer in 2003 and is headquartered in New York, NY.

Shutterstock Inc

Shutterstock is trending following the U.S. Department of Justice's clearance of its proposed merger with Getty Images, a major milestone that has sparked intense debate among investors regarding the combined entity's market position and the future of stock photography in an AI-driven landscape. While some community members view the potential merger as a strategic play to control essential training data for AI models, others are expressing skepticism over the deal's valuation, regulatory hurdles remaining in the U.K., and the long-term impact of generative AI on the core content business.

Solaris Energy Infrastructure, Inc. is a holding company, which engages in the manufacture of patented mobile proppant management systems that unload, store, and deliver proppant to oil and natural gas well sites. Its products include Mobile Proppant and Mobile Chemical Management Systems, and Inventory Management Software. The firm's services include field, last mile management, and transloading services. The company was founded by William A. Zartler in 2014 and is headquartered in Houston, TX.

Solaris Energy Infrastructure Inc. - Ordinary Shares - Class A

Solaris Energy Infrastructure is trending as investors focus on its role in providing essential power generation equipment for AI-driven data centers, a sector experiencing intense demand. The stock has seen significant attention due to its strategic partnerships, recent contract expansions, and strong relative strength in a challenging market, though community sentiment remains divided by legal challenges and short-seller reports.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silo Pharma's stock buzz increased on Wednesday after the company reported crucial development steps for SPC-15, their main product which serves as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).&nbsp;Silo entered into a partnership with Frontage Laboratories to perform a 7-day significant animal safety and toxicology study as requested by the FDA.&nbsp;Shares of the company closed at $0.84 on Wednesday, down 23.3% for the day, and declined further by 4.9% to $0.80 in after-hours trading.Silo is moving forward with an IND-enabling Good Laboratory Practice (GLP)-compliant toxicology and toxicokinetic study focused on SPC-15.Completing the toxicology studies with favorable outcomes will enable the submission of an IND application in 2025.&nbsp;Silo intends to start a first-in-human Phase 1 clinical trial for SPC-15 after receiving approval.&nbsp;The pharma company has obtained an exclusive worldwide license from Columbia University to develop SPC-15 further and enable its manufacturing and commercial distribution.Additionally, Silo also partnered with Veloxity Labs to provide bioanalysis services for its current GLP toxicology and toxicokinetics research.&nbsp;The company confirmed its plan to start the FDA IND process for SPC-15 in 2025, with the goal of advancing to clinical trials once approval is obtained.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 3,300% surge in 24-hour message volume.One user mentioned that buying shares under a dollar has been consistently profitable for them over the past five years, though they plan to exit within three to six months, adding that catching pre-market price spikes requires early mornings.&nbsp;<stembedurl>https://stocktwits.com/Helson/message/614607172</stembedurl>Another user noted they took a 9% gain on the stock and planned to exit soon.<stembedurl>https://stocktwits.com/Bdport/message/614597364</stembedurl>The stock has declined 12% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment

The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.

Equity

After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025

Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.

Silo Pharma (SILO) isn't your typical market mover. But on Tuesday, this small-cap biopharma stock defied expectations, skyrocketing over 123% to become the undisputed champion of U.S. gainers. The secret weapon? An exclusive global license agreement for a promising Alzheimer's drug.Wednesday's pre-market trading painted a different picture as the stock fell by as much as 13%, suggesting some investors are taking profits after the wild ride. However, at around 11 am ET, shares had rebounded, gaining over 2%.<figure class="image"><img style="aspect-ratio:1322/756;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SILO_stock_move_Jul_17_c1ed653683.png" alt="SILO stock move Jul 17" width="1322" height="756"><figcaption>SILO stock move Jul 17</figcaption></figure>But hold on, the story doesn't end there. SILO is still capturing retail investor attention like never before. Stocktwits data reveals a surge in interest: the stock has the most new watchers in the past 24 hours, and follower counts have skyrocketed by a whopping 453% over the past week.The excitement stems from a licensing deal for SPC-14, an Alzheimer's drug currently in preclinical development. Silo Pharma plans to leverage the FDA's streamlined pathway, potentially speeding up clinical trials and reducing costs.&nbsp;With the global Alzheimer's treatment market expected to reach a staggering $30.8 billion by 2033, the potential is undeniable.Retail investors on Stocktwits are buzzing, bullish about the deal's potential to supercharge SILO's value. This comes on the heels of a similar licensing agreement for their lead drug candidate targeting stress and PTSD.&nbsp;With shares already up 57% year-to-date and hitting 11-month highs, the latest development could still trigger a retail frenzy for SILO over the longer-term, despite the pre-market dip.Representative <a href="https://pixabay.com/illustrations/neurons-brain-cells-brain-structure-7420662/">image</a> by Gerd Altmann from Pixabay

Why This Small-Cap Biopharma Is Getting The Most Retail Attention On Stocktwits Today

Silo Pharma’s shares more than doubled yesterday, driven by a promising new Alzheimer’s drug agreement.

Silo Pharma’s shares more than doubled yesterday as retail investors flock to the stock, driven by a promising new Alzheimer’s drug agreement.

This account has been verified as an official SILO representative.

Verified Account

Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

SILO
SILO Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SILO News

SILOSILO Pharma Inc